Dr Caroline Barelle named “Rising Stars: Extraordinary Talent (2017)” at last night’s Scotland’s Life Sciences Dinner & Annual Awards. | 17.05.2018

17th May 2018: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that Dr Caroline Barelle was named as the winner in the “Rising Stars: Extraordinary Talent (2017)” category at last night’s Scotland’s Life Sciences Dinner & Annual Awards, held at the Hilton hotel Glasgow and attended by over 700 of Scotland’s top Life […]

Elasmogen CEO has been selected as a finalist for the Rising Stars | 29.01.2018

Dr. Caroline Barelle (CEO) has been selected as a finalist for the Rising Stars: Extraordinary Talent Award. Some of Scotland’s most dynamic life sciences companies and business leaders have been shortlisted for the prestigious Scottish Life Sciences Awards 2018. Read more here

Elasmogen CEO named one of top 14 Female Entrepreneurs in European Biotech by Labiotech.eu | 08.11.2017

Elasmogen’s CEO Dr Caroline Barelle has been named in Labiotech.eu’s list of top female entrepreneurs. Read the article here.

Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics | 09.05.2017

Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets   Aberdeen, Scotland and Quebec City, Canada; 9 May 2017: Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announce a research collaboration with Amgen, to develop […]

Elasmogen receives £1.2 M in grant and equity investment | 16.03.2017

Funding from Deepbridge Capital, Innovate UK and Scottish Investment Bank will support development of next generation Ophthalmology biologics   Thursday, 16 March 2017: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has received a Biomedical Catalyst Grant from the UK’s innovation agency, Innovate UK and matching investment from Deepbridge Capital and […]

Elasmogen Ltd – shark proteins for drug discovery | 20.01.2017

BBSRC support for research and commercialisation contributed to the creation of award-winning spin-out company Elasmogen by Dr Caroline Barelle and Professor Andrew Porter at the University of Aberdeen. The company is developing new medicines based on the discovery of certain antibody-like molecules found in sharks. IMPACT SUMMARY University of Aberdeen researchers Dr Caroline Barelle and […]

Elasmogen Ltd are shortlisted in the OBN Best Start-up Biotech Company Awards 2016 | 18.07.2016

Aberdeen, UK – [July 2016] OBN announced recently the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards remain independent and celebrate innovation across the UK life sciences industry and recognise achievements from emerging to late stage R&D companies, as well as life sciences investors. A judging […]

Elasmogen Ltd wins the “Perfect Pitch” at BioTrinity 2016 | 27.03.2016

Aberdeen, UK – [27th March 2016] As Europe’s leading biopartnering and investment conference, BioTrinity brings together investors, pharmaceutical executives and innovative life science R&D companies, from around the world. To mark BioTrinity’s 10th anniversary the new Perfect Pitch session has been introduced to their London meeting to increase the number of ways biotechnology companies can […]